GB0619611D0 - Compounds and their use - Google Patents

Compounds and their use

Info

Publication number
GB0619611D0
GB0619611D0 GBGB0619611.7A GB0619611A GB0619611D0 GB 0619611 D0 GB0619611 D0 GB 0619611D0 GB 0619611 A GB0619611 A GB 0619611A GB 0619611 D0 GB0619611 D0 GB 0619611D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0619611.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Priority to GBGB0619611.7A priority Critical patent/GB0619611D0/en
Publication of GB0619611D0 publication Critical patent/GB0619611D0/en
Priority to EP07824022A priority patent/EP2084140A1/en
Priority to JP2009530940A priority patent/JP2010505807A/en
Priority to CA002664842A priority patent/CA2664842A1/en
Priority to MX2009002606A priority patent/MX2009002606A/en
Priority to ZA200901399A priority patent/ZA200901399B/en
Priority to US12/439,523 priority patent/US8158789B2/en
Priority to CNA2007800371194A priority patent/CN101522648A/en
Priority to PCT/GB2007/003766 priority patent/WO2008040979A1/en
Priority to KR1020097006651A priority patent/KR20090060320A/en
Priority to US13/361,134 priority patent/US8227606B2/en
Priority to US13/493,110 priority patent/US20120269864A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
GBGB0619611.7A 2006-10-04 2006-10-04 Compounds and their use Ceased GB0619611D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0619611.7A GB0619611D0 (en) 2006-10-04 2006-10-04 Compounds and their use
KR1020097006651A KR20090060320A (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity
MX2009002606A MX2009002606A (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity.
JP2009530940A JP2010505807A (en) 2006-10-04 2007-10-04 Arginine derivative having NP-1 antagonist activity
CA002664842A CA2664842A1 (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity
EP07824022A EP2084140A1 (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity
ZA200901399A ZA200901399B (en) 2006-10-04 2007-10-04 Arginine derivatives with NP-1 antagonistic activity
US12/439,523 US8158789B2 (en) 2006-10-04 2007-10-04 Arginine derivatives with NP-I antagonistic activity
CNA2007800371194A CN101522648A (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity
PCT/GB2007/003766 WO2008040979A1 (en) 2006-10-04 2007-10-04 Arginine derivatives with np-i antagonistic activity
US13/361,134 US8227606B2 (en) 2006-10-04 2012-01-30 Arginine derivatives with NP-1 antagonistic activity
US13/493,110 US20120269864A1 (en) 2006-10-04 2012-06-11 Arginine Derivatives with NP-I Antagonistic Activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0619611.7A GB0619611D0 (en) 2006-10-04 2006-10-04 Compounds and their use

Publications (1)

Publication Number Publication Date
GB0619611D0 true GB0619611D0 (en) 2006-11-15

Family

ID=37453962

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0619611.7A Ceased GB0619611D0 (en) 2006-10-04 2006-10-04 Compounds and their use

Country Status (10)

Country Link
US (3) US8158789B2 (en)
EP (1) EP2084140A1 (en)
JP (1) JP2010505807A (en)
KR (1) KR20090060320A (en)
CN (1) CN101522648A (en)
CA (1) CA2664842A1 (en)
GB (1) GB0619611D0 (en)
MX (1) MX2009002606A (en)
WO (1) WO2008040979A1 (en)
ZA (1) ZA200901399B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914856D0 (en) * 2009-08-25 2009-09-30 Ark Therapeutics Ltd Compounds
KR102378975B1 (en) * 2020-10-16 2022-03-24 건양대학교산학협력단 Pharmaceutical composition comprising inhibitor of neuropilin-1 expression or activity for preventing or treating chronic rhinosinusitis
WO2022127654A1 (en) * 2020-12-16 2022-06-23 四川大学华西第二医院 Anti-fibrosis pharmaceutical composition and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (en) 1990-08-20 1994-03-11 Sanofi DERIVATIVES OF AMIDO-3 PYRAZOLE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH1059997A (en) * 1996-08-22 1998-03-03 Microbial Chem Res Found Amythiamicin amide derivative
HUP0003364A3 (en) 1997-06-19 2002-03-28 Sepracor Inc Marlborough Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB0207644D0 (en) * 2002-04-02 2002-05-15 Ark Therapeutics Ltd Peptides and their use
CN1829709A (en) * 2003-08-01 2006-09-06 健亚生物科技公司 Bicyclic imidazol derivatives against flaviviridae
RU2006145961A (en) * 2004-06-09 2008-07-20 Аванир Фармасьютикалс (Us) HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES
MX2007004051A (en) * 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3 kinases.
US20070249670A1 (en) * 2004-11-09 2007-10-25 Smithkline Beecham Corporation Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof

Also Published As

Publication number Publication date
US8227606B2 (en) 2012-07-24
MX2009002606A (en) 2009-04-30
ZA200901399B (en) 2010-06-30
US20120269864A1 (en) 2012-10-25
JP2010505807A (en) 2010-02-25
KR20090060320A (en) 2009-06-11
CA2664842A1 (en) 2008-04-10
US20120122862A1 (en) 2012-05-17
WO2008040979A1 (en) 2008-04-10
CN101522648A (en) 2009-09-02
US8158789B2 (en) 2012-04-17
US20100022525A1 (en) 2010-01-28
EP2084140A1 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
IL244442B (en) Substituted acylanilide compounds and uses thereof
TWI561237B (en) Substituted dihydropyrazolones and their use
HK1208000A1 (en) Thioninium compounds and their use
GB0701426D0 (en) Compounds and their use
HK1131922A1 (en) Phenylpropionamide compounds and the use thereof
GB0621160D0 (en) Compounds and uses thereof
IL194899A0 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
GB0611115D0 (en) Compounds and their use
EP2124908A4 (en) Compounds and uses thereof
EP2069371A4 (en) Organo-arsenoxide compounds and use thereof
EP2120563A4 (en) Compounds and uses thereof
GB0619611D0 (en) Compounds and their use
IL192820A0 (en) Novel compounds and use thereof
EP2099459A4 (en) Compounds and uses thereof
HUP0600122A3 (en) New compounds and their use
EP2120957A4 (en) Compounds and uses thereof
GB0616577D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use
GB0619609D0 (en) Compounds and their use
GB0619610D0 (en) Compounds and their use
GB0614091D0 (en) Compounds and their uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)